title: [Antiatherogenic effect of Radix Salviae Miltiorrhizae and Fructus Crataegi on experimental atherosclerosis in rats].
abstract: OBJECTIVE
  To investigate the antiatherogenic effect and possible mechanisms of the extracts of Radix Salviae Miltiorrhizae (RSM) or Fructus Crataegi (FC), as well as their interaction.
  
  
  METHODS
  Wistar rats were randomly divided into 2 groups: normal group and model group. The atherosclerotic model rats were injected VD3 and ovalbumin, while fed with high cholesterol diet. After the model was determined successfully, all model rats were divided into normal group, model group, Xuezhikang group, RSM group, FC group, mixture of RSM and FC group. Each group was given the corresponding drugs for 4 weeks. After 12 weeks, blood serum were analyzed for total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C), superoxide dismutase ( SOD), malondialdehyde (MDA) and nitric oxide (NO). And the blood plasma also analyzed for levels of endothelin (ET), 6-keto prostaglandin F1alpha (6-keto-PGF1alpha), thromboxane B2 (TXB2), C-reactive protein (CRP), interleukin 6 (IL-6), interleukin 8 (IL-8), tumor necrosis factor alpha (TNF-alpha) and so on. At last, the pathological observation of aorta was carried out.
  
  
  RESULTS
  Compared with those in model group, the TC, TG, LDL-C, ET, TXB2 and MDA levels and TXB2/PGF1alpha ratio were reduced, while the HDL-C, the serum SOD, No and 6-keto-PGF1alpha level were raised in the intervention groups. Although the levels of CRP, IL-6 and IL-8 were lower than model group, there was no obvious effect on the releasing of TNF-alpha.
  
  
  CONCLUSIONS
  RSM and FC could inhibit the atherogenesis formation and development, which might be due to regulating the lipid metabolism, enhancing the antioxidation, and reducing the release of inflammatory factors.
authors.affiliation: Institute of Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Bin
authors.initials: B
authors.lastname: Yang
authors.forename: Lan
authors.initials: L
authors.lastname: Wang
authors.forename: Rixin
authors.initials: R
authors.lastname: Liang
authors.forename: Chengyu
authors.initials: C
authors.lastname: Chen
authors.forename: Nan
authors.initials: N
authors.lastname: Hu
authors.forename: Long
authors.initials: L
authors.lastname: Cheng
authors.forename: Yan
authors.initials: Y
authors.lastname: Yang
authors.forename: Xiaojie
authors.initials: X
authors.lastname: Yin
authors.forename: Shuangrong
authors.initials: S
authors.lastname: Gao
authors.forename: Jinxi
authors.initials: J
authors.lastname: Ye
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000517:prevention & control*; D002097:C-Reactive Protein / Q000032:analysis; D027825:Crataegus; D004195:Disease Models, Animal; D015850:Interleukin-6 / Q000097:blood; D015227:Lipid Peroxidation / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008297:Male; D010936:Plant Extracts / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D027561:Salvia miltiorrhiza
chemical_list: D015850:Interleukin-6; D008055:Lipids; D010936:Plant Extracts; D002097:C-Reactive Protein